|
1.4 Biologie - Technos
|
|
|
DNA Barcodes Make for Better Single-Cell Analysis [NIH Director's Blog]
|
|
|
|
|
|
The
team’s rather simple but ingenious approach relies on attaching a
unique combination of two DNA barcodes to each cell prior to analyzing
epigenetic marks all across the genome, making it possible for
researchers to pool hundreds of cells without losing track of each of
them individually.
|
|
|
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
New additions to the cancer precision medicine toolkit [Genome Medicine]
|
|
|
|
|
|
New
computational and database-driven tools are emerging to aid in the
interpretation of cancer genomic data as its use becomes more common in
clinical evidence-based cancer medicine. Two such open source tools,
published recently in Genome Medicine, provide important advances to
address the clinical cancer genomics data interpretation bottleneck.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
5.9 AACR
|
|
|
|
Advancing Patient Care Through Focused Innovation [NCI]
|
|
|
|
|
|
A
third principle is that the staggering heterogeneity of cancer demands
new approaches, new understanding of the molecular and cellular biology
of cancer, new ways of conducting clinical trials, scientists with
different training, and new ways of harnessing data.
|
|
|
|
|
|
|
These are the top priorities for the nation’s top cancer doctor [Washington Post]
|
|
|
|
|
|
For
the past several months, Sharpless has been on a “listening tour” at
NCI, talking to employees, patients, outside researchers and industry
experts. Now he’s detailing his plans, beginning with his appearance in
Chicago on Monday. Here’s what is on his mind, based on the speech and
an interview with The Washington Post.
|
|
|
|
|
|
|
5.9.3 AACR - mélanome
|
|
|
|
5.9.4 AACR - poumon
|
|
|
|
|
|
|
|
|
|
|
Merck Immunotherapy Drug Shines In Lung Cancer Study [NPR]
|
|
|
|
|
|
Doctors
already prescribe Keytruda to patients if a blood test shows that they
are likely to respond to this drug. But Merck, the company that makes
it, wanted to find out how the drug works in patients who aren't obvious
candidates as determined by that blood test.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Lung Cancer Patients Live Longer With Immune Therapy [NY Times]
|
|
|
|
|
|
“I’ve
been treating lung cancer for 25 years now, and I’ve never seen such a
big paradigm shift as we’re seeing with immunotherapy,” said Dr. Roy
Herbst, Chief of Medical Oncology at the Yale Cancer Center. He was not
involved in the pembrolizumab study.
|
|
|
|
|
|
|
5.9.5 AACR - CAR-T
|
|
|
|
5.9.7 AACR - divers
|
|
|
|
6.6 Publications
|
|
|
Tighten Up Your Numbers! [In the Pipeline]
|
|
|
|
|
|
Ioannidis
is upfront about the fact that his suggested new threshold is not the
final answer, but just an interim step towards larger reforms. He wants
to see better experimental and trial designs (Bayesian and traditional),
larger sample sizes, and more attention paid to potential sources of
bias and to effect size.
|
|
|
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|